A randomized, placebo‐controlled study of the NS 5B inhibitor beclabuvir with peginterferon/ribavirin for HCV genotype 1-Reference-Cited by-同舟云学术

A randomized, placebo‐controlled study of the NS 5B inhibitor beclabuvir with peginterferon/ribavirin for HCV genotype 1

Published:2014-12-15 Issue:8 Volume:22 Page:658-664
ISSN:1352-0504
Container-title:Journal of Viral Hepatitis
language:en
Short-container-title:J Viral Hepat

Author:

Tatum H.¹,Thuluvath P. J.²,Lawitz E.³,Martorell C.⁴,DeMicco M.⁵,Cohen S.⁶,Rustgi V.⁷,Ravendhran N.⁸,Ghalib R.⁹,Hanson J.¹⁰,Zamparo J.¹¹,Zhao J.¹²,Cooney E.¹¹,Treitel M.¹³,Hughes E.¹³

Affiliation:

1. Options Health Research Tulsa OK USA

2. Mercy Medical Center Baltimore MD USA

3. The Texas Liver Institute University of Texas Health Science Center San Antonio TX USA

4. The Research Institute Springfield MA USA

5. Associated Gastroenterology/Advanced Clinical Research Institute Anaheim CA USA

6. University Hospital/Case Western Medical Center Cleveland OH USA

7. Metropolitan Research Arlington VA USA

8. Digestive Disease Associates Baltimore MD USA

9. Texas Clinical Research Institute Arlington TX USA

10. Charlotte Gastroenterology and Hepatology Charlotte NC USA

11. Bristol‐Myers Squibb Wallingford CT USA

12. Bristol‐Myers Squibb Hopewell NJ USA

13. Bristol‐Myers Squibb Princeton NJ USA

Publisher

Wiley

Subject

Virology,Infectious Diseases,Hepatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/jvh.12372

Reference21 articles.

1. Sofosbuvir for Previously Untreated Chronic Hepatitis C Infection

2. 1425 SIMEPREVIR (TMC435) WITH PEGINTERFERON/RIBAVIRIN FOR CHRONIC HCV GENOTYPE-1 INFECTION IN TREATMENT-NAÏVE PATIENTS: RESULTS FROM QUEST-1, A PHASE III TRIAL

3. 1413 SIMEPREVIR (TMC435) WITH PEGINTERFERON/RIBAVIRIN FOR TREATMENT OF CHRONIC HCV GENOTYPE-1 INFECTION IN TREATMENT-NAÏVE PATIENTS: RESULTS FROM QUEST-2, A PHASE III TRIAL

4. 1418 DACLATASVIR COMBINED WITH PEGINTERFERON ALFA-2A AND RIBAVIRIN FOR 12 OR 16 WEEKS IN PATIENTS WITH HCV GENOTYPE 2 OR 3 INFECTION: COMMAND GT2/3 STUDY

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The repurposing of FDA-approved drugs to stop viral replication in COVID-19 treatment: a comprehensive molecular docking and dynamics analysis;Research Journal of Biotechnology;2023-11-05

2. Curing Hepatitis C with Direct‐Acting Antiviral Therapy;New Drug Development for Known and Emerging Viruses;2021-12-03

3. Antiviral and Antimicrobial Nucleoside Derivatives: Structural Features and Mechanisms of Action;Molecular Biology;2021-11

4. Discovery of Potent SARS-CoV-2 Inhibitors from Approved Antiviral Drugs via Docking and Virtual Screening;Combinatorial Chemistry & High Throughput Screening;2021-03

5. RNA-dependent RNA polymerase (RdRp) inhibitors: The current landscape and repurposing for the COVID-19 pandemic;European Journal of Medicinal Chemistry;2021-03